Technology | Integrative Care

MammoScreen AI Tool Improves Diagnostic Performance of Radiologists in Detecting Breast Cancer
December 16, 2020

This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.

Preliminary Results Suggest AB-MR Detects Breast Cancers that 3-D Mammograms May Miss
November 29, 2020

This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.

Modeling Tool Guides CRC Treatment Strategies with More Precision
October 27, 2020

“This algorithm could allow us a better shot at personalized medicine and enhance our ability to tailor the treatments to be as appropriate as possible,” said study author Daniel Chang, MD.

Tzvia Bader on the TrialJectory Clinical Trial Tool
August 25, 2020

The chief executive officer and co-founder of TrialJectory spoke about the online tool and what it offers for patients, providers, and pharmaceutical companies.

Radiomics Model May Predict Survival Outcomes Among Patients Diagnosed with Lung Cancer
July 31, 2020

This study created and assessed a parsimonious radiomic model that was able to identify a vulnerable subset of screen-detected lung cancers that are associated with poor outcome.

Hydrogel Spacer Appears Effective for Men Receiving Prostate Radiotherapy
July 26, 2020

In this study, investigators found that the hydrogel spacer has a favorable risk-benefit profile for patients receiving radiotherapy for prostate cancer.

DeepSurv Displays Possible Benefits in Prognostic Evaluation, Treatment Recommendation
July 20, 2020

The deep learning survival neural network model demonstrated the potential to provide personalized treatment recommendations based on real clinical data in patients with non-small cell lung cancer.

Cellectar opens manufacturing facility for radiolabeled CLR1404
January 01, 2008

Cellectar opens manufacturing facility for radiolabeled CLR1404

High cost of breast MRI screening appears to be justified
January 01, 2008

MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the United States if new American Cancer Society guidelines

Breast MRI reveals occult cancers in PBI candidates
January 01, 2008

Breast MRI identifies mammographically occult secondary tumors in about 6% of women with early-stage breast cancer who would otherwise qualify for partial breast irradiation